Burke R L
Chiron Corporation, Emeryville, California 94608.
Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S906-11. doi: 10.1093/clind/13.supplement_11.s906.
A herpes simplex virus subunit vaccine has been tested for immunogenicity and protective efficacy in animal models. The vaccine is a mixture of the viral glycoproteins gB and gD expressed in mammalian cells as secreted carboxyl terminal truncated derivatives. The antigens have been combined with several adjuvants, including a lipophilic derivative of a muramyl tripeptide, MTP-PE, and administered in a stable, low-oil emulsion. Titers of antibody that are threefold to 15-fold greater than those obtained with alum and within twofold of those generated with complete Freund's adjuvant are elicited in animals, including primates. Prophylactic immunization of guinea pigs provides nearly complete protection against intravaginal challenge with herpes simplex virus type 2. Treatment of previously infected guinea pigs reduces the frequency and severity of recurrent disease, although variations in efficacy dependent on the antigen, adjuvant, and dosing regimen employed are observed. The immunogenicity of this vaccine in animals provides the rationale for further testing in human clinical trials.
一种单纯疱疹病毒亚单位疫苗已在动物模型中进行了免疫原性和保护效力测试。该疫苗是在哺乳动物细胞中表达的病毒糖蛋白gB和gD的混合物，作为分泌型羧基末端截短衍生物。这些抗原已与几种佐剂结合，包括胞壁酰三肽的亲脂性衍生物MTP-PE，并以稳定的低油乳液形式给药。在包括灵长类动物在内的动物中，所诱导的抗体滴度比用明矾获得的滴度高3至15倍，且在使用完全弗氏佐剂产生的滴度的两倍范围内。豚鼠的预防性免疫几乎能完全保护其免受2型单纯疱疹病毒的阴道内攻击。对先前感染的豚鼠进行治疗可降低复发性疾病的频率和严重程度，尽管观察到疗效因所用抗原、佐剂和给药方案的不同而有所差异。这种疫苗在动物中的免疫原性为在人类临床试验中进行进一步测试提供了理论依据。
